Previous 10 | Next 10 |
Lumos Pharma ([[LUMO]]) has commenced Phase 2b OraGrowtH210 trial evaluating oral LUM-201 in pediatric growth hormone deficiency ((PGHD)) patients.The trial will evaluate three dose levels of LUM-201 against a comparator arm of standard-of-care injectable growth hormone therapy.The purpose of...
Lumos Pharma, Inc. (LUMO) Q3 2020 Results Earnings Conference Call November 10, 2020, 04:30 PM ET Company Participants Lisa Miller - Director, IR Rick Hawkins - CEO, President, and Chairman John McKew - COO and CSO Eugene Kennedy - CMO Carl Langren - CFO Conference Call Participants Yasmeen R...
Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a c...
AUSTIN, Texas, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to ...
AUSTIN, Texas, Oct. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, today announced it will report its third quarter 2020 financial results after market close on Tuesday, November 10, 20...
AUSTIN, Texas, Aug. 27, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will present and host one-on-one meetings at the following virtual investor conferences to ...
Immunic (NASDAQ: IMUX ) is up 16.2% after hours - rebounding from a regular-session decline of 5.7% - after Piper Sandler named it one of its best ideas for biotech "bargain shopping." More news on: Immunic, Inc., Lumos Pharma, Inc., Amarin Corporation plc, Healthcare stocks news, News...
The following slide deck was published by Lumos Pharma, Inc. in conjunction with their 2020 Q2 earnings Read more ...
Lumos Pharma, Inc. (LUMO) Q2 2020 Earnings Conference Call August 13, 2020 4:30 p.m. ET Company Participants Lisa Miller - Director, IR Rick Hawkins - CEO, President, and Chairman John McKew - COO and Chief Scientific Officer Gene Kennedy - Chief Medical Officer Carl Langren ...
Lumos Pharma (NASDAQ: LUMO ) : Q2 GAAP EPS of -$0.65 beats by $0.05 . Revenue of $0.03M Press Release More news on: Lumos Pharma, Inc., Earnings news and commentary, Healthcare stocks news, ,
News, Short Squeeze, Breakout and More Instantly...
AUSTIN, Texas, July 23, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a late-stage biopharmaceutical company focused on therapeutics for rare diseases, announced it will report second quarter 2024 financial results after the market close on Thursday, August 1, 2024. The company w...
AUSTIN, Texas, June 04, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced today details of new analyses of data from its Phase 2 OraGrowtH212 clinical trial presented in two posters at the...
AUSTIN, Texas, May 20, 2024 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical stage biopharmaceutical company focused on therapeutics for rare diseases, announced today that new analyses of data from its Phase 2 OraGrowtH210 and OraGrowtH212 clinical trials have been accepted f...